FOXD3-AS1

Across TCGA pan-cancer cohorts, FOXD3-AS1 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of FOXD3-AS1’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where FOXD3-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FOXD3-AS1 is over-expressed in tumor, although a few such as COAD and THCA show the opposite, repressed pattern.

LUAD, COAD, and THCA are the cancer types where FOXD3-AS1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FOXD3-AS1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	All	+1.466	<.001	11	view →
COAD	Male	II,III,IV	−1.064	<.001	11	view →
THCA	All	II,III,IV	−0.169	<.001	9	view →
HNSC	Male	II,III,IV	+0.865	<.001	8	view →
BRCA	All	III,IV	+1.916	<.001	6	view →
LUSC	Female	All	+1.699	<.001	6	view →
STAD	All	All	−0.662	.002	5	view →
READ	All	All	−1.325	.006	2	view →
PRAD	All	All	+0.765	<.001	2	view →
BLCA	All	IV	−0.694	.002	2	view →
KIRC	All	All	−0.061	.011	2	view →
CHOL	All	All	+1.420	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

FOXD3-AS1–LUAD

Open the LUAD breakdown →